{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(5)"],"submitter":["Wollenhaupt J"],"funding":["Pfizer"],"pubmed_abstract":["<h4>Objectives</h4>This post hoc analysis evaluated change from baseline (Δ) in weight/body mass index (BMI) and association with disease activity or lipid changes in tofacitinib-treated patients with rheumatoid arthritis (RA).<h4>Methods</h4>Data up to month 12 were pooled from eight phase 3 and 3b/4 studies of patients with RA receiving tofacitinib 5 or 10 mg twice daily or tofacitinib 11 mg modified-release once daily (alone or combined with conventional synthetic disease-modifying antirheumatic drugs), or placebo. Assessments included Δweight/BMI and the proportion of patients with weight gain ≥5%, at months 3, 6, and 12. Correlations between ∆weight/∆BMI and baseline/∆Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR]), baseline C-reactive protein (CRP),"],"journal":["ACR open rheumatology"],"pagination":["e70040"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12062792"],"repository":["biostudies-literature"],"pubmed_title":["Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis."],"pmcid":["PMC12062792"],"pubmed_authors":["Wollenhaupt J","Shapiro A","Chapman DS","Richez C","Lukas C","Ruyssen-Witrand A","Rivas JL","Daien C","Morel J","Citera G","Cros M"],"additional_accession":[]},"is_claimable":false,"name":"Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis.","description":"<h4>Objectives</h4>This post hoc analysis evaluated change from baseline (Δ) in weight/body mass index (BMI) and association with disease activity or lipid changes in tofacitinib-treated patients with rheumatoid arthritis (RA).<h4>Methods</h4>Data up to month 12 were pooled from eight phase 3 and 3b/4 studies of patients with RA receiving tofacitinib 5 or 10 mg twice daily or tofacitinib 11 mg modified-release once daily (alone or combined with conventional synthetic disease-modifying antirheumatic drugs), or placebo. Assessments included Δweight/BMI and the proportion of patients with weight gain ≥5%, at months 3, 6, and 12. Correlations between ∆weight/∆BMI and baseline/∆Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR]), baseline C-reactive protein (CRP),","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T18:04:21.204Z","creation":"2026-05-19T03:07:07.298Z"},"accession":"S-EPMC12062792","cross_references":{"pubmed":["40344335"],"doi":["10.1002/acr2.70040"]}}